Cargando…

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

INTRODUCTION: Insulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration. Here we describe the molecular engineering and the biological and pharmacological properties of insulin icodec. RESEARCH DESIGN AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimura, Erica, Pridal, Lone, Glendorf, Tine, Hansen, Bo Falk, Hubálek, František, Kjeldsen, Thomas, Kristensen, Niels Rode, Lützen, Anne, Lyby, Karsten, Madsen, Peter, Pedersen, Thomas Åskov, Ribel-Madsen, Rasmus, Stidsen, Carsten Enggaard, Haahr, Hanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378355/ https://www.ncbi.nlm.nih.gov/pubmed/34413118 http://dx.doi.org/10.1136/bmjdrc-2021-002301

Ejemplares similares

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
por: Hansen, Bo F., et al.
Publicado: (2012)

Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2011)

Molecular engineering of safe and efficacious oral basal insulin
por: Hubálek, Frantisek, et al.
Publicado: (2020)

Author Correction: Molecular engineering of safe and efficacious oral basal insulin
por: Hubálek, Frantisek, et al.
Publicado: (2020)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
por: Pieber, Thomas R., et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus
por: Plum-Mörschel, Leona, et al.
Publicado: (2023)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

Systematic Evaluation of the Metabolic to Mitogenic Potency Ratio for B10-Substituted Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2012)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Abstract 141: CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: A post hoc analysis
por: Chandrappa, Manu, et al.
Publicado: (2022)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
por: Silva, Rodrigo Ribeiro e, et al.
Publicado: (2023)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

Novel Covalently Linked Insulin Dimer Engineered to Investigate the Function of Insulin Dimerization
por: Vinther, Tine N., et al.
Publicado: (2012)

Increased insulin receptor binding and increased IGF-1 receptor binding are linked with increased growth of L6hIR cell xenografts in vivo
por: Hvid, Henning, et al.
Publicado: (2020)

Retinol-Binding Protein 4 in Twins: Regulatory Mechanisms and Impact of Circulating and Tissue Expression Levels on Insulin Secretion and Action
por: Ribel-Madsen, Rasmus, et al.
Publicado: (2009)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

LBSUN210 Efficacy And Safety Profile Of Insulin Icodec Versus Insulin Glargine U100 In Type 2 Diabetes Mellitus: A Meta-Analysis Of Randomized Controlled Trials
por: Dimayuga, Diana Colleen, et al.
Publicado: (2022)

Dually Reactive Long Recombinant Linkers for Bioconjugations as an Alternative to PEG
por: Kjeldsen, Thomas, et al.
Publicado: (2020)

DNA methylation and gene expression of HIF3A: cross-tissue validation and associations with BMI and insulin resistance
por: Main, Ailsa Maria, et al.
Publicado: (2016)

Does DNA Methylation of PPARGC1A Influence Insulin Action in First Degree Relatives of Patients with Type 2 Diabetes?
por: Gillberg, Linn, et al.
Publicado: (2013)

Correction: Does DNA Methylation of PPARGC1A Influence Insulin Action in First Degree Relatives of Patients with Type 2 Diabetes?
por: Gillberg, Linn, et al.
Publicado: (2013)

Plasma ceramide levels are altered in low and normal birth weight men in response to short-term high-fat overfeeding
por: Ribel-Madsen, Amalie, et al.
Publicado: (2018)

Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to tricarboxylic acid cycle capacity in young, healthy low birth weight men
por: Ribel‐Madsen, Amalie, et al.
Publicado: (2016)

Plasma amino acid levels are elevated in young, healthy low birth weight men exposed to short‐term high‐fat overfeeding
por: Ribel‐Madsen, Amalie, et al.
Publicado: (2016)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Agonism and Antagonism at the Insulin Receptor
por: Knudsen, Louise, et al.
Publicado: (2012)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang, Fei, et al.
Publicado: (2012)

Insulin signalling in tanycytes gates hypothalamic insulin uptake and regulation of AgRP neuron activity
por: Porniece Kumar, Marta, et al.
Publicado: (2021)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
por: Bue-Valleskey, Juliana M., et al.
Publicado: (2023)

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)
por: Moyers, Julie S, et al.
Publicado: (2021)

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
por: Kildegaard, Jonas, et al.
Publicado: (2019)

A Hundred Years of Insulin Innovation: When Science Meets Technology
por: Kjeldsen, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_46jbvqeppvv13t8o07n1djcuvq